Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Ralph Brandenberger, Chief Technical Officer of Nkarta, Inc. (NASDAQ:NKTX), recently sold 7,447 shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at an average price of $2.20 each, amounting to a total transaction value of $16,383. The transaction comes as Nkarta's stock trades near its 52-week low of $2.08, having declined over 70% in the past year. According to InvestingPro analysis, the company appears undervalued at its current market cap of $175 million.
The sale was made to satisfy tax withholding obligations related to the vesting and settlement of Restricted Stock Units, as specified in the award terms. Following this transaction, Brandenberger holds 124,796 shares of Nkarta stock. While the company maintains a strong liquidity position with cash exceeding debt and a current ratio of 12.9, InvestingPro subscribers can access 8 additional key insights about Nkarta's financial health and market position in the comprehensive Pro Research Report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.